×
For best experience we recommend to activate Javascript in your browser.
NFE2L1 antibody (C-Term)
This anti-NFE2L1 antibody is a Rabbit Polyclonal antibody detecting NFE2L1 in WB and ELISA. Suitable for Human.
Quick Overview for NFE2L1 antibody (C-Term) (ABIN2324943)
Target
See all NFE2L1 Antibodies
NFE2L1
(Nuclear Factor (erythroid-Derived 2)-Like 1 (NFE2L1))
Reactivity
All reactivities for NFE2L1 antibodies
Human
Host
All hosts for NFE2L1 antibodies
Rabbit
Clonality
All clonalities for NFE2L1 antibodies
Polyclonal
Conjugate
All conjugates for NFE2L1 antibodies
This NFE2L1 antibody is un-conjugated
Application
All applications for NFE2L1 antibodies
Western Blotting (WB), ELISA
Product Details anti-NFE2L1 Antibody
(hide)
Binding Specificity
All epitopes for NFE2L1 antibodies
AA 712-742, C-Term
Cross-Reactivity
Human, Mouse (Murine)
Cross-Reactivity (Details)
Calculated cross reactivity: Hu Mo
Characteristics
NFE2L1, CT (NFE2L1, HBZ17, NRF1, TCF11, Nuclear factor erythroid 2-related factor 1, Locus control region-factor 1, Nuclear factor, erythroid derived 2, like 1, Transcription factor 11, Transcription factor HBZ17, Transcription factor LCR-F1)
Purification
Purified by Protein A affinity chromatography.
Immunogen
NFE2L1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 712-742 amino acids from the C-terminal region of human NFE2L1.
Isotype
IgG
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working conditions should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Buffer
Supplied as a liquid in PBS, pH 7.2, 0.09 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C
Storage Comment
-20°C
Target Details for NFE2L1
(hide)
Target
NFE2L1
(Nuclear Factor (erythroid-Derived 2)-Like 1 (NFE2L1))
Alternative Name
NFE2L1
NCBI Accession
NP_003195
UniProt
Q14494
Recently viewed
(hide)
Chat with us , powered by LiveChat